Oncological needs in transgender patients.

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-10-01 Epub Date: 2025-04-18 DOI:10.1007/s12094-025-03917-x

Francisco Ayala de la Peña, David Martínez-Ramos, Oscar Juan-Vidal, Marcelino Gómez-Balaguer, Maria Miguélez, David Páez, Virginia Arrazubi, Carmen Hinojo González

{"title":"Oncological needs in transgender patients.","authors":"Francisco Ayala de la Peña, David Martínez-Ramos, Oscar Juan-Vidal, Marcelino Gómez-Balaguer, Maria Miguélez, David Páez, Virginia Arrazubi, Carmen Hinojo González","doi":"10.1007/s12094-025-03917-x","DOIUrl":null,"url":null,"abstract":"<p><p>Transgender people encounter unique health disparities in oncology. They face substantial barriers in accessing healthcare that are exaggerated by bias/discrimination from healthcare professionals and systems, and socio-economic marginalisation. This review explores the current landscape of cancer risk, screening and management in transgender individuals from a Spanish perspective. Nationwide data are lacking, but estimates from Madrid suggest that 22 per 100,000 individuals are transgender. The needs of the transgender individual for gender-affirming surgeries and gender-affirming hormone therapy may alter the individual's oncological risk profile and likelihood of receiving appropriate screening, and when diagnosed with cancer may have to be balanced against treatment requirements (e.g., endocrine therapy for breast cancer). There remain unmet needs in the oncological care of the transgender patient. Concerted effort is required to address clinical research gaps, and reform healthcare education and policy, in order to develop inclusive clinical practices that enhance patient care and outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3849-3859"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460380/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03917-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Transgender people encounter unique health disparities in oncology. They face substantial barriers in accessing healthcare that are exaggerated by bias/discrimination from healthcare professionals and systems, and socio-economic marginalisation. This review explores the current landscape of cancer risk, screening and management in transgender individuals from a Spanish perspective. Nationwide data are lacking, but estimates from Madrid suggest that 22 per 100,000 individuals are transgender. The needs of the transgender individual for gender-affirming surgeries and gender-affirming hormone therapy may alter the individual's oncological risk profile and likelihood of receiving appropriate screening, and when diagnosed with cancer may have to be balanced against treatment requirements (e.g., endocrine therapy for breast cancer). There remain unmet needs in the oncological care of the transgender patient. Concerted effort is required to address clinical research gaps, and reform healthcare education and policy, in order to develop inclusive clinical practices that enhance patient care and outcomes.

Abstract Image

查看原文本刊更多论文

跨性别患者的肿瘤需求。

跨性别者在肿瘤学中遇到独特的健康差异。他们在获得卫生保健方面面临巨大障碍，而来自卫生保健专业人员和系统的偏见/歧视以及社会经济边缘化加剧了这种障碍。这篇综述从西班牙的角度探讨了跨性别者癌症风险、筛查和管理的现状。缺乏全国范围的数据，但马德里的估计表明，每10万人中有22人是变性人。变性人对性别确认手术和性别确认激素治疗的需求可能会改变个体的肿瘤风险状况和接受适当筛查的可能性，并且当被诊断患有癌症时，可能必须与治疗需求（例如，乳腺癌的内分泌治疗）相平衡。在跨性别患者的肿瘤护理方面仍有未满足的需求。需要协调一致的努力来解决临床研究差距，改革医疗保健教育和政策，以发展包容性的临床实践，提高患者护理和结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.